Protara Therapeutics Ownership

TARA Stock  USD 3.50  0.02  0.57%   
Protara Therapeutics owns a total of 34.76 Million outstanding shares. The majority of Protara Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Protara Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Protara Therapeutics. Please pay attention to any change in the institutional holdings of Protara Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Protara Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Protara Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

Protara Stock Ownership Analysis

About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Protara Therapeutics recorded a loss per share of 2.64. The entity last dividend was issued on the 10th of January 2020. The firm had 1:40 split on the 10th of January 2020. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. Artara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. To find out more about Protara Therapeutics contact the company at 646 844 0337 or learn more at https://www.protaratx.com.

Protara Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Levy Richard S over a month ago
Acquisition by Levy Richard S of 10000 shares of Protara Therapeutics at 2.85 subject to Rule 16b-3
 
Fabbio Patrick over a month ago
Acquisition by Fabbio Patrick of 23500 shares of Protara Therapeutics subject to Rule 16b-3
 
Zummo Jacqueline over a month ago
Disposition of 6554 shares by Zummo Jacqueline of Protara Therapeutics at 4.76 subject to Rule 16b-3
 
Hannah Fry over a month ago
Disposition of 4 shares by Hannah Fry of Protara Therapeutics at 6.14 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3
 
Jesse Shefferman over three months ago
Insider Trading
 
Opaleye Management Inc. over three months ago
Disposition of 1600 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7141 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 subject to Rule 16b-3
 
Jesse Shefferman over three months ago
Insider Trading
 
Jesse Shefferman over six months ago
Disposition of 3300 shares by Jesse Shefferman of Protara Therapeutics subject to Rule 16b-3
 
Opaleye Management Inc. over six months ago
Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3
 
Opaleye Management Inc. over six months ago
Disposition of 15000 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4034 subject to Rule 16b-3

Protara Therapeutics Outstanding Bonds

Protara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protara bonds can be classified according to their maturity, which is the date when Protara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.